Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

met pre-defined specifications and were released for clinical use in the PEARL-SC clinical study. The data from these GMP campaigns were submitted to FDA as a part of the Comparability Plan for blisibimod.

Management

  • Anthera announced the promotion of Dr. Debra Odink to the role of Chief Technology Officer and Senior Vice President.  Dr. Odink has served as Anthera's Senior Vice President of Pharmaceutical Research and Development since 2005.  Dr. Odink assumes the responsibility of overseeing all aspects of clinical pharmacology, non-clinical sciences product and process development activities.

  • *SELENA-SLEDAI -- Safety of Estrogen in Lupus Erythematosus National Assessment / Systemic Lupus Erythematosus Activity Index is a cumulative, weighted index of systemic lupus erythematosus disease activity.

    About Anthera Pharmaceuticals

    Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623).  Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF) which have been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.  

    Safe Harbor Statement

    Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, f
    '/>"/>

    SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2015)... April 20, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... oncology and drug-delivery therapies, today shared highlights of ... for Cancer Research (AACR) annual meeting. Halozyme also ... randomized Phase 2 study in pancreatic cancer, Study ... the American Society of Clinical Oncology (ASCO). ...
    (Date:4/20/2015)... Calif. , April 20, 2015  Published ... positive trends in the ability of Neuraltus ... progression of amyotrophic lateral sclerosis (ALS, also known ... 6-month treatment period. While NP001,s slowing of decline ... study was not statistically significant, clinically meaningful slowing ...
    (Date:4/20/2015)... Md. , April 20, 2015  OpGen, ... announced the expansion of its executive management team ... FMI ) executive Kevin Krenitsky , ... as interim chief financial officer. ... leading and managing global diagnostic and biotechnology operations, ...
    Breaking Medicine Technology:Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 2Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 4Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 5Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 2OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 3OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 4
    ... RainDance Technologies, Inc. and Ambry Genetics, today ... and commercialization of a comprehensive drug absorption, distribution, ... use on next-generation sequencing (NGS) systems. The announcement ... Toxicology,s 50th Annual Meeting in Washington, D.C. Financial ...
    ... General Nutrition Company (GNC) today announced a license ... for a line of more than two dozen branded ... will range from heart rate and blood pressure monitors ... The products will be distributed through ...
    Cached Medicine Technology:RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis 2RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis 3RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis 4GNC Teams With Sakar International for Branded Health and Wellness Product Line 2GNC Teams With Sakar International for Branded Health and Wellness Product Line 3
    (Date:4/20/2015)... Global Lyme Alliance (GLA) announced today that ... the Hyatt Regency Greenwich, raised over $850,000 to fund ... debilitating tick-borne diseases. , “We are extremely grateful ... made this year’s Gala such a success,” said Robert ... education initiatives to ultimately find a cure for ...
    (Date:4/20/2015)... OR (PRWEB) April 20, 2015 The NFL ... which type of players to add to their rosters, both ... the field. In this episode of SCI TV , ... Cowboys' recent acquisition of Greg Hardy given increased attention on ... than a year after the Ray Rice scandal brought media ...
    (Date:4/20/2015)... Huntsville, AL (PRWEB) April 20, 2015 A ... that when participants were asked to list the top 10 ... when asked to list the 10 most harmful therapies, only ... drugs is that although they may help, their effect is ... consistently,” said Dr. Beck in a recent interview. , “On ...
    (Date:4/20/2015)... Washington, DC (PRWEB) April 20, 2015 “Consumers ... using aftershave, or washing their children’s hair will not put ... President and CEO of the National Alliance for Hispanic Health, ... too long the FDA has not had authority to ensure ... are safe nor has FDA had authority to get products ...
    (Date:4/20/2015)... 2015 Novatus, a leading provider ... its service level to the growing European market ... and Paris. After a rigorous review process ... of resilience, security and operational expertise, and extensive ... Novatus as we expand our footprint and capabilities ...
    Breaking Medicine News(10 mins):Health News:Global Lyme Alliance's “Time for Lyme” Gala Raises Over $850,000 for Tick-Borne Disease Research 2Health News:Global Lyme Alliance's “Time for Lyme” Gala Raises Over $850,000 for Tick-Borne Disease Research 3Health News:Character Concerns in the NFL with Vinnie Iyer on SCI TV 2Health News:Medical Doctor in Huntsville Reveals That Aerobic Exercise Offers Best Results in Fibromyalgia Treatment 2Health News:Statement of National Alliance for Hispanic Health on Senate Introduction of Personal Care Products Safety Act 2Health News:Novatus Expands into European Data Centers 2
    ... blame, Japanese study finds , , THURSDAY, Dec. 11 (HealthDay News) ... new Japanese study finds. , Those living in multigenerational households ... more likely to be diagnosed with serious heart disease than ... researchers at Osaka University reported in the Dec. 11 online ...
    ... the age of 90, living well beyond the age of 100 and ... the secret to the fountain of youth. And now, this information is ... ... Wire EON) December 11, 2008 -- Natural Health News Report is ...
    ... 11 The Susan G. Komen for the Cure(R),Advocacy Alliance ... the next Secretary of Health and Human Services and director ... Alliance noted that,Daschle has long been a leader on health ... years related to breast cancer. , ...
    ... for Americans to "Tell Their Stories" , ... has indicated that healthcare reform will be a top priority ... offer to serve as health and human services secretary, is ... asking Americans to help with reform efforts by sharing their ...
    ... Philadelphia, 11 December 2008 Heart failure (HF) clinics ... patients with heart failure, yet there have been no ... clinics. To address this gap, the Quality of ... (HFSA) has developed a consensus statement summarizing the rationale, ...
    ... aim to strengthen science in selected member states of ... Member States hosting the grantees finance the grants entirely. ... the Czech Republic, Estonia, Hungary, Poland, Portugal and Turkey. ... to five years to help them establish their groups ...
    Cached Medicine News:Health News:Crowded Households Raise Women's Heart Risk 2Health News:Crowded Households Raise Women's Heart Risk 3Health News: Anti-Aging Miracle Physicians Have Been Waiting for is Finally Here : Free Book Available From Natural Health News Report Reveals the Secret to Staying Young 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Applauds Selection of Senator Tom Daschle for HHS Secretary, White House Health Reform Czar 2Health News:Hospice Community Encouraged to Respond to Daschle Request to Participate in Information Gathering about Healthcare Concerns 2Health News:New statement outlines essentials of heart failure clinics 2
    ... The Rotanta 460 family ... extraordinary line that meets ... demands. They feature high ... Their state-of-the-art technology and ...
    ... 15 centrifuge provides all the ... for today's full-service clinical lab ... a speed up to 15,300 ... spin tubes, plates and rotors ...
    ... Autocrit Ultra has an uniquely ... a facility in which tubes ... in the same carrying tray. ... built-in magnifier, quiet operation, automatic ...
    The Spinchron 15 centrifuge provides all the versatility and high capacity needed for today's full-service clinical lab needs. This centrifuge is available in a nonrefrigerated model with a speed up ...
    Medicine Products: